Most people want to work remotely — companies want them back in-office
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
14 hours ago
- CTV News
Quebec endures impacts of U.S. tariffs as layoffs begin
Watch One business has closed, and others have begun to layoff employees as U.S. tariffs take their tole on the Quebec lumber industry. CTV's Swidda Rassy reports.
Globe and Mail
2 days ago
- Globe and Mail
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia's common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.69 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release.
CTV News
2 days ago
- CTV News
Canada-U.S. trade talks ‘difficult to discern' after deadline passes: Reid
Watch CTV News Political Commentator Scott Reid on why he believes there's 'not much reason for optimism' after Trump hiked tariffs following the trade deal deadline.
